Veno-occlusive disease (VOD) of the liver is a complication observed particularly in patients undergoing hematopoietic stem cell transplantation (HSCT). Defibrotide (DF) is a polydeoxyribonucleotide with aptameric activity on endothelium. We evaluated in a retrospective analysis the efficacy of DF in pediatric patients developing hepatic VOD after HSCT. A total of 45 patients between 0.2 and 20 years (median age: 8.2 years) with hepatic VOD were treated with DF: 22 patients (49%) met risk criteria for severe or progressive disease and 23 (51%) for moderately severe and mild disease. The median duration of DF treatment was 17 days. In all, 34 patients (76%) achieved complete response (CR) with a survival rate of 64% at day 100. CR rate in patients with severe disease was 50% with longterm survival of 36%. The average DF dose in the CR group was 45 mg/kg/day and in the no responder (NR) group 27 mg/kg/day. The use of additional drugs besides DF to treat VOD made no difference in the outcome compared to DF alone. The average interval from diagnosis to start of DF was 1 day in the CR and 5.5 days in NR group. In multivariate analysis, early intervention remained the only significant factor for a CR.
brotide; child; treatment outcome; multiple-organ failure; restrospective studies Veno-occlusive disease (VOD) of the liver is a lifethreatening complication of intensive chemotherapy mostly, but not exclusively associated with allogeneic or autologous HSCT. It is characterized by right upper quadrant pain, hepatomegaly, fluid retention, ascites, weight gain and hyperbilirubinemia. VOD usually occurs before day þ 30 after transplantation. 1, 2 The incidence of this complication in the pediatric population after allogeneic HSCT is reported between 5 and 40% with a tendency to increase in recent years. [3] [4] [5] [6] [7] [8] The diagnosis of VOD is primarily based on clinical findings.
Risk factors for VOD have been described 9 and include second transplants with myeloablative regimens, 10 hepatic inflammation, 2, 11 prior abdominal irradiation, 8 extensive hepatic fibrosis or cirrhosis 12, 13 and patients beyond the second relapse scheduled for a myeloablative allogeneic transplantation. 7, 9 Recently gemtuzumab ozogamicin (Mylotarg, CMA-676, Wyeth), an immunoconjugate consisting of a humanized anti-CD33 antibody linked to the cytotoxic compound N-acetyl gamma calicheamicin dimethylhydrazine, was reported to increase the risk for VOD during HSCT. [14] [15] [16] [17] [18] [19] Several inborn errors treated by HSCT are associated with an increased risk of developing VOD including osteopetrosis (OP), 20 congenital macrophage activation syndromes (MAS, ie hemophagocytic lymphohistiocytosis) and metachromatic leukodystrophy (MLD). Nevertheless, a substantial number of cases are observed outside defined risk groups.
The outcome of patients with mild or moderate VOD is usually good. Severe VOD, however, especially when associated with multiorgan failure (MOF) has a high mortality, which may exceed 90%. 2, 21 Defibrotide (DF, Prociclide s , Gentium, Como, Italy) is a single-stranded polydeoxyribonucleotide derived from porcine tissue, which possesses antithrombotic, thrombolytic, anti-inflammatory and anti-ischemic properties. 22 DF has affinity for the adenosine receptors A1 and A2 causing thrombin antagonism in vitro. In preclinical studies, DF exerted a protective effect on injured microvasculature. [23] [24] [25] Early retrospective clinical trials 26, 27 of DF in mostly adult patients who fulfilled criteria for severe VOD demonstrated encouraging responses. A single arm cohort study 28 and a prospective randomized trial of mostly adult patients with severe VOD confirmed these findings, clearly indicating efficacy of DF in the treatment of established VOD. 29 We report here results of a retrospective analysis in a group of 45 children and adolescents treated with DF for hepatic VOD after HSCT. The data suggest that, in children, DF is an effective treatment modality in severe disease with a high benefit upon early intervention and a trend for the need of higher doses compared to those used in adults.
Patients and methods

Patients
Enrolled in this study were children and adolescents younger than 20 years with autologous or allogeneic HSCT who were treated with DF for diagnosed VOD after IRBtype approval was obtained. The data were collected retrospectively from 12 unselected European centers. Participation was based only on the presence of patients with VOD treated with DF without forehand knowledge of their clinical outcomes using a standardized questionnaire. The Study period was from October 1998 to October 2002.
Methods
Criteria for the diagnosis of VOD
Patients were diagnosed with VOD based on the Baltimore criteria, 30 which included jaundice with bilirubin 434.2 mmol/l (2 mg/dl) as well as two or more of the following: hepatomegaly, right upper quadrant (RUQ) pain, ascites and weight gain greater than 5%. Other causes for the observed signs and symptoms were excluded by clinical assessment at the time of diagnosis of VOD.
Definition of high-risk criteria for VOD
The following criteria were used to assess risk factors for the development of VOD: increased serum AST level prior to transplantation ('transaminitis'), prior liver disease (including prior VOD), prior abdominal radiation, Karnofsky (416 years of age) and Lansky (o16 years of age) performance scores less than 90%; second myeloablative SCT, patients beyond the second relapse scheduled for a myeloablative allogeneic transplantation, patients transplanted after treatment with Mylotarg and patients transplanted for the diagnosis of OP. In the group of patients with solid tumors, the diagnosis of NB and age younger than 7 years were included as high-risk criteria. 8 MAS and MLD are considered risk factors based on a consensus achieved at a meeting of the inborn error working party (Vitznau/Switzerland, 2002). We categorized patients according to their cumulative risk factors into 'high risk' with at least one of the above-mentioned risk criteria and 'low risk' with none of the above.
Assessment of the severity of disease
The severity of VOD for mild and moderate disease was defined retrospectively according to established criteria. 2 Mild disease is clinically obvious VOD without intervention and moderate disease is VOD that requires treatment, but resolves completely.
Severe VOD was based on the presence of MOF, in addition to VOD, which was defined as either an oxygen requirement with an oxygen saturation of o90% on room air and/or ventilator dependence, and/or renal dysfunction (defined as doubling of baseline creatinine and/or dialysis dependence) and/or encephalopathy. 26 In order for MOF to be VOD -related, it had to be present within 28 days after the diagnosis of VOD.
Definition of complete response (CR)
CR was defined as resolution of VOD-and MOF-related symptoms together with a bilirubin decrease to less than 34.2 mmol/l (2 mg/dl). Patients who failed to achieve CR were defined as no responders (NR).
Defibrotide administration, dose calculation and toxicity DF was administered i.v. in crystalloid solution (either NS or D5W), as four divided doses per day over 2-4 h. Daily doses were increased incrementally to individual maximum potential daily doses depending on response and tolerance without adverse events attributable to DF. The total dose, the duration of treatment and the weight were recorded. The DF dose was calculated in mg/kg/day and rounded to the nearest 5 mg. Toxicity is reported according to standard CTC criteria.
Statistical analysis
Fisher's exact test was used for independent categorical variables and Student's t-test when testing independent continuous variables. A multiple logistic regression model could only be applied to assess the impact of the day of intervention with DF and the DF dose.
Results
Patients, disease and HSCT characteristics
A total of 45 patients, 19 female and 26 male with a median age of 8.2 years (range 0.2-20 years) were included. In all, 34 patients (76%) were transplanted for malignant and 11 (24%) for nonmalignant diseases. These included acute lymphoblastic leukemia (n ¼ 6), acute myeloid leukemia
and MLD (n ¼ 1). All received high-dose chemotherapy for conditioning prior to HSCT except one patient with a relapsed AML who received Mylotarg for compassionate use after allogeneic HSCT. A total of 84% received a busulfan-based chemotherapy, 73% were treated with cyclophosphamide, in 44% melphalan was part of the chemotherapy, 9% of the patients received fludarabine and two were treated with total body irradiation. The remaining patients were treated with different combinations of myeloablative chemotherapy including thiotepa and etoposide.
Hematopoietic stem cell sources consisted of unmanipulated bone marrow in 27% of the patients, unmanipulated peripheral blood stem cells (PBSC) in 40% and T-celldepleted PBSC in 29%. One patient received umbilical cord blood. Of the patients, 18% received an autologous, 29% a Defibrotide for hepatic VOD in children S Corbacioglu et al matched related donor (MRD), 29% a matched unrelated donor graft (MUD). In total, 13% of the patients had a mismatched related (MMRD) and 9% a mismatched unrelated donor (MMUD) ( Table 1) .
Prophylaxis, diagnosis, severity of VOD and risk factors
A total of 80% of the patients (n ¼ 36) received medication for the prevention of VOD. This consisted of a low-dose heparin monotherapy (100 U/kg/day) in 64% (n ¼ 23), 14%
(n ¼ 5) received a combination of heparin and ursodiol, 11% (n ¼ 4) a combination of heparin and ATIII, 5.5% (n ¼ 2) a combination of heparin and L-glutamine and 5.5% (n ¼ 2) received ursodiol as the only prophylaxis; 20% (n ¼ 9) received no prophylaxis. The median day of diagnosis of VOD was day þ 12 post transplant (range 0-58). The presenting symptoms were RUQ pain in 69% (n ¼ 31), weight gain in 82% (n ¼ 37) and an increased abdominal circumference in 84% (n ¼ 38). Ultrasound-confirmed hepatomegaly was present in 91% Table 2 ). The risk of developing severe VOD based on the presence or absence of the risk criteria was assessed: 51% (n ¼ 23) of the children had at least one risk factor to develop VOD, 61% (14/23) of the patients with at least one high risk factor developed severe VOD compared to 36% (8/22) with no risk factors. Although the data show a trend, the two groups were not significantly different (Fisher exact: P ¼ 0.089). 
Defibrotide: administration, duration of use, actual given dose
The median delay to start DF was 1 day after the diagnosis of VOD (range 0-12 days). The median duration of treatment with DF was 17 days (range 1-83 days). The median given dose of DF was 40 mg/kg/day (range 10-110 mg/kg/day). Prophylactic measures like low-dose heparin were not discontinued after treatment with DF was initiated. Five patients received one or more additional treatment modalities concurrently with DF. These drugs consisted of AT III in three, low molecular weight heparin in two and prostaglandin E2, t-PA, protein C concentrate and C1 esterase inhibitor in one each ( Table 2 ).
Outcome
The overall CR rate was 76% (34/45) with 64% (29/45) surviving beyond day þ 100. The CR rate within the group of patients with severe VOD was 50% (11/22) with a longterm survival beyond day þ 100 of 36% (8/22). Of the five patients with limited long-term survival, three had a relapse and two succumbed to pulmonary aspergillosis and adenoviral infection. The CR rate of patients who were treated with DF only was 75% (18/24) and in patients receiving additional treatment it was 76% (16/21) . This was also the case in the subgroup of patients with severe disease. The median age of patients with a CR was not different from patients with NR (9.672.4 vs 6.873.6 years). We analyzed the effect of the dosage of DF on the outcome of VOD. The average DF dose in the CR group was 4577 mg/kg/day and in the NR group 27710 mg/kg/day (Po0.01). The average delay from diagnosis of VOD to start of DF was 170.5 day in the CR group and 5.572 days in the NR group (Po0.01). This was also observed in the group of patients with severe disease (1.3 vs 5.5 days; Po0.01). Owing to the small patient number, multivariate analyses on all variables were not possible. Therefore, the analysis was limited to the dose of DF and the delay to start of treatment, two parameters with a high clinical relevance, using a logistic regression model. Evaluating the data under these conditions, a maximum delay of 1 day to start of treatment vs more than 1 day delay from the diagnosis of VOD remained the only significant predictor of CR (Table 2) .
Toxicity
In 35% (n ¼ 16) of the patients, coagulation abnormalities were observed, which were grade 1 in 10 patients according to CTC criteria, and grade 2 in four patients. Coagulopathy, however, was present prior to the administration of DF and thus could not be attributed to DF. In all but two patients they consisted of abnormal laboratory parameters like prolonged PT and/or PTT as well as hypofibrinogenemia without clinical correlation. None of the mild coagulation abnormalities led to the discontinuation of DF. A total of 66% percent (9/16) of the patients with coagulation abnormalities suffered from severe disease.
In 7% (n ¼ 3) DF was discontinued. One critically ill patient with severe VOD presented with intracranial hemorrhage and succumbed to severe gastrointestinal bleeding (Patient #26). This patient suffered prior to the onset of VOD from consumptive coagulopathy needing replacement therapy. The onset of VOD aggravated the coagulopathy prior to the start of DF. His average DF dose was 25 mg/kg/day. One patient with moderate VOD presented with convulsions on day þ 16 (Patient #19). A cerebral MRI confirmed a parenchymal and ventricular hemorrhage of the left parieto-temporal region with extension to the occiput. The patient received DF for 6 days and the average DF dose in this case was 40 mg/kg/ day. The possible causes were evaluated and the event was attributed to DF after known vascular and coagulation disorders were excluded. The patient is alive and well over 1 year post transplant with a persistent right-sided visual impairment. In both cases, a causal correlation with the administration of DF could not be established and no other treatment modality was used in addition to DF. Overall, the average DF dose in patients with reported coagulation disorders was lower compared to the group with no reported side effects (30 vs 45 mg/kg/day). Nevertheless, 69% (11/16) of the patients with coagulation disorders had a CR.
In one case, DF was stopped due to diarrhoea (Patient #40). No other grade 3 or 4 toxicity attributable to the administration of DF was reported ( Table 2) .
Discussion
In this report, we describe the experience of therapeutic DF for VOD in children and adolescents after high-dose chemotherapy and HSCT. The overall CR rate was 76% with a long-term survival of 64%. In the group of patients with severe VOD, the CR rate was 50% with a survival beyond day þ 100 of 36%. None of the patients with the limited long-term survival died of VOD-related causes. These data corroborate the data deduced from the subpopulation of 15 children and adolescents in the report of Chopra et al. 27 These authors reported an overall CR rate of 80% (n ¼ 12 of 15 children under 20 years) with a long-term survival of 53%. In the group of patients with severe disease (n ¼ 9), the CR rate was 67% with a longterm survival of 44%. Early reports on VOD found no difference in outcome between children and adults. 31 An ongoing phase II, randomized study of adult and pediatric patients with severe disease recently reported a CR rate in the adult subpopulation of 50% (n ¼ 30) and in the pediatric subpopulation of 63% (n ¼ 16). 29 The better outcome in the pediatric subpopulation has not reached significance in this study (personal communication). A single arm study of 88 mostly adult patients achieved a CR rate of 36%. 28 Therefore, it remains to be determined if children with severe VOD have a better outcome when treated with DF compared to adults.
Although the data presented here were obtained from a retrospectively collected multicenter patient population, it nevertheless appears, in univariate analyses, that children had an improved outcome when receiving on average more Defibrotide for hepatic VOD in children S Corbacioglu et al than 40 mg/kg/day of DF. In contrast, in a recent study in mostly adult patients with severe VOD, the majority of responses were observed with dosages of DF between 20 and 40 mg/kg/day. 28 An ongoing prospective therapeutic study that includes pediatric patients might be able to give an answer to this observed discrepancy.
There is no effective treatment modality for VOD, which is firmly established. Studies on other drugs in VOD treatment are limited to case reports and small series. Most experience exists with tissue plasminogen activator (tPA), which achieved responses in less than a third of patients. 32, 33 A recent pediatric series reported on 12 children with VOD including five with MOF who were treated with tPA. The survival in the five patients with severe VOD was only 20%. 34 TPA may be associated with fatal hemorrhage and its use is not recommended in the presence of MOF. 32, 35 In our series, the outcome was not influenced by the addition of other treatment modalities besides DF.
So far, DF was found to be well tolerated. [27] [28] [29] 36 In the retrospective study presented here, about a third of patients were reported with some form of coagulopathy of which the majority occurred in patients with severe disease and independently of the DF treatment. In almost all patients DF was not discontinued. Furthermore, a dose-dependent effect could not be established and the majority of patients with coagulation disorders recovered fully. DF was discontinued in only two cases where a severe bleeding disorder was observed. These events could not be clearly attributed to DF. We therefore agree with the reported benign toxicity profile of DF.
Early treatment with DF in patients with severe VOD was associated with a better outcome and remained in a multivariate logistic model, the only significant predictor of CR. Owing to the several unsuccessful attempts to identify superior early predictors of VOD, the Baltimore 30 and Seattle 2 criteria are still widely used to diagnose VOD despite their relatively low sensitivity of 56%. 37 This emphasizes the problem that effective treatment might be delayed to a point where major sinusoidal endothelial and small vessel damage has already occurred. Nevertheless, due to the retrospective nature of the study, the possibility of a bias in the comparison of patients who received different timing and dose of DF cannot be excluded. With sufficient numbers of patients, a multivariate analysis would be possible to take clinical differences between patients into account.
Several drugs have been studied in the prophylaxis of VOD. [38] [39] [40] [41] [42] Heparin, which is widely used for prophylaxis, was demonstrated more recently in a large prospective cohort study of the European Group for Blood and Marrow Transplantation (EBMT) to be of no benefit. 21 In a retrospective study in children, heparin was also found not to decrease the incidence of VOD.
3 Although Ursodeoxycholic acid (ursodiol) was reported to reduce the severity of VOD in two randomized trials 43, 44 another randomized trial 45 of heparin plus ursodiol vs heparin alone showed no benefit of ursodiol. Similarly in a large randomized Scandinavian study, ursodiol compared to heparin alone demonstrated no preventive anti-VOD effect. 46 The observed efficacy of DF in children with severe VOD, the low toxicity profile of the drug and in particular the definite advantage of early rather than late intervention are important arguments to also evaluate the prophylactic use of DF in a pediatric population at high risk for VOD.
